Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study

International Journal of DermatologyVolume 59, Issue 5 p. e136-e137 Correspondence Treatment of chronic alopecia areata with tildrakizumab: an open-label pilot study Karolina L. S. Kerkemeyer MBBS (Honours), BHlthSci, Corresponding Author karolina.kerkemeyer@sinclairdermatology.com.au orcid.org/0000-0001-9367-2348 Sinclair Dermatology, East Melbourne, Victoria, AustraliaSearch for more papers by this authorRodney Sinclair MBBS, MD, FACD, orcid.org/0000-0001-6751-1428 Sinclair Dermatology, East Melbourne, Victoria, AustraliaSearch for more papers by this author Karolina L. S. Kerkemeyer MBBS (Honours), BHlthSci, Corresponding Author karolina.kerkemeyer@sinclairdermatology.com.au orcid.org/0000-0001-9367-2348 Sinclair Dermatology, East Melbourne, Victoria, AustraliaSearch for more papers by this authorRodney Sinclair MBBS, MD, FACD, orcid.org/0000-0001-6751-1428 Sinclair Dermatology, East Melbourne, Victoria, AustraliaSearch for more papers by this author First published: 03 March 2020 https://doi.org/10.1111/ijd.14826Citations: 1 Funding sources: Sun Pharmaceutical Industries Ltd. for compassionate supply of tildrakizumab Conflict of interest: Professor Sinclair has served as an investigator in clinical trials sponsored by Sun Pharmaceutical Industries Ltd. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume59, Issue5May 2020Pages e136-e137 RelatedInformation